Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 3Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Smoking Cessation 1Prostatic Hyperplasia 1Precancerous Conditions 1Papillomavirus Infections 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Colonic Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 30Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 20Papillomavirus Vaccines 9Radiotherapy, Intensity-Modulated 4Cisplatin 4Blood Specimen Collection 4fludarabine 3Vaccines, Synthetic 3Engerix-B 3Cyclophosphamide 3halofantrine 2fludarabine phosphate 2aldesleukin 2Watchful Waiting 2Vaccines 2Patient Navigation 2Paclitaxel 2Light Coagulation 2Interleukin-2 2Imiquimod 2Human Papillomavirus Recombinant Vaccine nonavalent 2Hepatitis A Vaccines 2Fluorouracil 2Electrocoagulation 2Cetuximab 2Carboplatin 2Albumin-Bound Paclitaxel 2utomilumab 1polyphenon E 1infigratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Papillomavirus Infections × polyphenon E × Clear all
NCT00303823 2015-05-05

Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia

National Cancer Institute (NCI)

Phase 2 Completed
98 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡